NewLink Looks To Nix Investor Suit Over Cancer Drug, Again
Biopharmaceutical company NewLink Genetics Corp. urged a New York federal court Tuesday to dismiss for a second time a proposed investor class action alleging executives' misrepresentations about a pancreatic cancer treatment...To view the full article, register now.
Already a subscriber? Click here to view full article